Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients

BACKGROUND: It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. RESULTS: A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Holden, Inge K., Bistrup, Claus, Nilsson, Anna Christine, Hansen, Janne Fuglsang, Abazi, Rozeta, Davidsen, Jesper Rømhild, Poulsen, Mikael Kjær, Lindvig, Susan Olaf, Justesen, Ulrik S., Johansen, Isik Somuncu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447120/
https://www.ncbi.nlm.nih.gov/pubmed/34237179
http://dx.doi.org/10.1111/joim.13361
_version_ 1784569003670241280
author Holden, Inge K.
Bistrup, Claus
Nilsson, Anna Christine
Hansen, Janne Fuglsang
Abazi, Rozeta
Davidsen, Jesper Rømhild
Poulsen, Mikael Kjær
Lindvig, Susan Olaf
Justesen, Ulrik S.
Johansen, Isik Somuncu
author_facet Holden, Inge K.
Bistrup, Claus
Nilsson, Anna Christine
Hansen, Janne Fuglsang
Abazi, Rozeta
Davidsen, Jesper Rømhild
Poulsen, Mikael Kjær
Lindvig, Susan Olaf
Justesen, Ulrik S.
Johansen, Isik Somuncu
author_sort Holden, Inge K.
collection PubMed
description BACKGROUND: It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. RESULTS: A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. CONCLUSION: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid‐19 vaccination.
format Online
Article
Text
id pubmed-8447120
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84471202021-09-17 Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients Holden, Inge K. Bistrup, Claus Nilsson, Anna Christine Hansen, Janne Fuglsang Abazi, Rozeta Davidsen, Jesper Rømhild Poulsen, Mikael Kjær Lindvig, Susan Olaf Justesen, Ulrik S. Johansen, Isik Somuncu J Intern Med Research Letters BACKGROUND: It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is sufficient to elicit an immune response in solid organ transplant (SOT) recipients. RESULTS: A total of 80 SOT recipients completed a two‐dose regimen with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA vaccine. Only 35.0% (n = 28) were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine. CONCLUSION: This emphasizes that SOT recipients need continued use of personal protective measures. Future studies need to closely examine the cellular immune response in patients with compromised antibody response to Covid‐19 vaccination. John Wiley and Sons Inc. 2021-08-09 2021-12 /pmc/articles/PMC8447120/ /pubmed/34237179 http://dx.doi.org/10.1111/joim.13361 Text en © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Letters
Holden, Inge K.
Bistrup, Claus
Nilsson, Anna Christine
Hansen, Janne Fuglsang
Abazi, Rozeta
Davidsen, Jesper Rømhild
Poulsen, Mikael Kjær
Lindvig, Susan Olaf
Justesen, Ulrik S.
Johansen, Isik Somuncu
Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title_full Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title_fullStr Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title_full_unstemmed Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title_short Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
title_sort immunogenicity of sars‐cov‐2 mrna vaccine in solid organ transplant recipients
topic Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447120/
https://www.ncbi.nlm.nih.gov/pubmed/34237179
http://dx.doi.org/10.1111/joim.13361
work_keys_str_mv AT holdeningek immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT bistrupclaus immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT nilssonannachristine immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT hansenjannefuglsang immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT abazirozeta immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT davidsenjesperrømhild immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT poulsenmikaelkjær immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT lindvigsusanolaf immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT justesenulriks immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients
AT johansenisiksomuncu immunogenicityofsarscov2mrnavaccineinsolidorgantransplantrecipients

Ejemplares similares